Waregem (Belgium)/Rotterdam (the Netherlands)*, 16 April 2010 – In the first quarter of 2010, the consolidated turnover of Arseus increased 7.4% to € 96.8 million. Organic growth was 3.2%.
Ger van Jeveren, CEO of Arseus: “Arseus had a strong start of 2010 with turnover growth of 7.4%, of which 3.2% was organic growth. The result achieved by Arseus Medical in particular deserves a compliment. In spite of the phase out of a number of activities with low gross margins, Arseus Medical had sufficient resilience for realising an organic growth of 3.6%. The persistently strong result achieved by Fagron is due to the successful revitalisation of pharmaceutical compounding in Europe designed to provide for the growing need for tailor-made medication. Corilus in 2010 took up where it left off in 2009; with the successful rollout of its software in Europe. Arseus Dental experienced a difficult start of 2010, but achieved good results in March. The activities in Switzerland and the activities related to dental laboratories exhibited initial signs of recovery in March. It is however still too early to say whether this represents a structural recovery.
We look to the future with confidence and consequently confirm the expectations for 2010 that we announced earlier.”
Unaudited management figures (x 1,000 euro) Q1 2010 Q1 2009 Evolution Organic growth Fagron 38,633 34,633 11.5% 7.6% Arseus Dental 38,423 37,919 1.3% -0.6% Arseus Medical 12,632 10,535 19.9% 3.6% Corilus 7,103 7,015 1.3% 1.3% Total 96,791 90,132 7.4% 3.2%
* This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the full press release: